Organosyn Life Sciences Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Organosyn Life Sciences Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $838.6K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Organosyn Life Sciences Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $838.6K Trade | TransData Nexus

Organosyn Life Sciences Private Limited

Indian Pharmaceutical Exporter · Nutritional Supplements Specialist · $838.6K Total Trade · DGFT Verified

Organosyn Life Sciences Private Limited is an Indian pharmaceutical exporter with a total trade value of $838.6K across 2 products in 1 therapeutic categories. Based on 28 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Chondroitin ($419.3K), Glucosamine ($419.3K), .

Organosyn Life Sciences Private Limited — Export Portfolio & Destination Treemap

Organosyn Life Sciences Private Limited pharmaceutical export portfolio — 2 products across 1 therapeutic categories. Source: Indian Customs (DGFT).

Who is Organosyn Life Sciences Private Limited? — Company Overview & Market Position

Organosyn Life Sciences Private Limited is a pharmaceutical company established on August 11, 2011, in Hyderabad, Telangana, India. The company is registered under the Corporate Identification Number (CIN) U24100TG2011PTC150729. It operates as a private limited company with an authorized capital of ₹20.00 crore and a paid-up capital of ₹9.70 crore. The registered office is located at Hno 3-1-2 Plot No 17 Motivalley Goyal Colony Tirumalgherry Hyderabad 500015, Hyderabad, Telangana, 500015.

The company's primary focus is on the manufacture and marketing of high-quality generic pharmaceutical formulations. It specializes in solid oral dosage forms, including tablets, capsules, and dry powders in bottles and sachets. Additionally, Organosyn Life Sciences has a dedicated hormonal facility for tablets and capsules. The manufacturing plants have an annual capacity of approximately 2 billion units and are approved by various regulatory agencies, including the UK's MHRA, Australia's TGA, Health Canada, and SAUMP Ukraine.

What Does Organosyn Life Sciences Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Chondroitin$419.3K

Product Portfolio — Top 2 by Export Value

Organosyn Life Sciences Private Limited exports 2 pharmaceutical products across 1 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Chondroitin	Nutritional Supplements	$419.3K	14	8.2%	5
2	Glucosamine	Nutritional Supplements	$419.3K	14	3.2%	10

Organosyn Life Sciences Private Limited exports 2 pharmaceutical products across 1 therapeutic categories with a total export value of $838.6K. The top category is Nutritional Supplements (100.0% of portfolio), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Organosyn Life Sciences Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Organosyn Life Sciences Private Limited operates a manufacturing unit through its joint venture with GIL Agrotech (India) Pvt. Ltd., known as Evertogen Lifesciences Ltd. Evertogen specializes in the production of solid oral dosage forms, such as tablets, capsules, and dry powders in bottles and sachets. The facility also includes a dedicated hormonal production area for tablets and capsules. With an annual capacity of approximately 2 billion units, the plant is equipped with modernized equipment and has received approvals from regulatory agencies like the UK's MHRA, Australia's TGA, Health Canada, and SAUMP Ukraine.

3Key Leadership

The leadership team of Organosyn Life Sciences Private Limited includes:

Manav Jassal: Director since December 29, 2012.

Sat Paul Jassal: Director since June 8, 2016.

The company has also had past directors, including Arun Prakash, Raminder Kaur, and Roopal Jain.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Organosyn Life Sciences Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Organosyn Life Sciences Private Limited has made significant strides in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The manufacturing facility, Evertogen Lifesciences Ltd., has obtained approvals from several regulatory agencies, including the UK's MHRA, Australia's TGA, Health Canada, and SAUMP Ukraine. These approvals indicate the company's commitment to meeting international quality standards. However, specific details regarding regulatory filings, approvals, and market access status in the U.S., EU, UK, Australia, and Japan are not readily available in the provided sources.

2Emerging Markets

Organosyn Life Sciences Private Limited has expanded its presence in emerging markets, notably in Africa, Latin America, and Southeast Asia. The company acquired the branded formulation business from Synmedic Ltd. in 2011, a company established in Ukraine since 1996, which has a wide range of products in different therapeutic segments. This acquisition has enabled Organosyn to establish a marketing base in Ukraine and Central Asia. The company has marketing offices in Ukraine and Kazakhstan and is involved in the promotion and marketing of branded formulations through its team of highly motivated and trained professionals.

Geographic Strategy

Organosyn Life Sciences Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific information regarding Organosyn Life Sciences Private Limited's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not readily available in the provided sources. The company's manufacturing facility, Evertogen Lifesciences Ltd., has received approvals from regulatory agencies such as the UK's MHRA, Australia's TGA, Health Canada, and SAUMP Ukraine, indicating compliance with international quality standards. However, details pertaining to the FDA are not specified.

2WHO & EU GMP

Organosyn Life Sciences Private Limited's manufacturing facility, Evertogen Lifesciences Ltd., has received approvals from various regulatory agencies, including the UK's MHRA, Australia's TGA, Health Canada, and SAUMP Ukraine. However, specific information regarding WHO prequalification, EU GMP certificates, and EDQM status is not available in the provided sources.

3CDSCO & Indian Regulatory

Organosyn Life Sciences Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

Organosyn Life Sciences Private Limited operates in the competitive pharmaceutical industry, focusing on the manufacture and marketing of high-quality generic formulations. The company's manufacturing facility, Evertogen Lifesciences Ltd., has received approvals from various regulatory agencies, including the UK's MHRA, Australia's TGA, Health Canada, and SAUMP Ukraine, indicating compliance with international quality standards. However, specific information regarding the company's market share, top competitors, and head-to-head analysis is not readily available in the provided sources.

2Key Differentiators

Organosyn Life Sciences Private Limited differentiates itself through its manufacturing facility, Evertogen Lifesciences Ltd., which has an annual capacity of approximately 2 billion units. The facility is approved by various regulatory agencies, including the UK's MHRA, Australia's TGA, Health Canada, and SAUMP Ukraine, indicating compliance with international quality standards. Additionally, the company's acquisition of Synmedic Ltd.'s branded formulation business in 2011 has enabled it to establish a marketing base in Ukraine and Central Asia, expanding its global footprint.

3Strategic Position

Buyer Due Diligence Brief — Evaluating Organosyn Life Sciences Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Organosyn Life Sciences Private Limited has demonstrated a consistent track record in the pharmaceutical industry, focusing on the manufacture and marketing of high-quality generic formulations. The company's manufacturing facility, Evertogen Lifesciences Ltd., has an annual capacity of approximately 2 billion units and is approved by various regulatory agencies, including the UK's MHRA, Australia's TGA, Health Canada, and SAUMP Ukraine, indicating compliance with international quality standards. The acquisition of Synmedic Ltd.'s branded formulation business in 2011 has enabled the company to establish a marketing base in Ukraine and Central Asia, expanding its global footprint. Specific details regarding the company's export volume, consistency, and reliability indicators are not readily available in the provided sources.

2Certifications to Verify

Importers should verify the following certifications when considering Organosyn Life Sciences Private Limited as a supplier:

FDA Facility Registration: To ensure compliance with U.S. regulatory standards.

Frequently Asked Questions — Organosyn Life Sciences Private Limited

How many pharmaceutical products does Organosyn Life Sciences Private Limited export from India?

Organosyn Life Sciences Private Limited exports 2 pharmaceutical products across 1 therapeutic categories. The top exports are Chondroitin ($419.3K), Glucosamine ($419.3K). Total export value is $838.6K.

What is Organosyn Life Sciences Private Limited's total pharmaceutical export value?

Organosyn Life Sciences Private Limited's total pharmaceutical export value is $838.6K, based on 28 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Organosyn Life Sciences Private Limited cover?

Organosyn Life Sciences Private Limited exports across 1 therapeutic categories. The largest are Nutritional Supplements (100.0%, 2 products).

Get Full Organosyn Life Sciences Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.